{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Refractory+Prostate+Cancer",
    "query": {
      "condition": "Hormone Refractory Prostate Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 925,
    "total_pages": 93,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Refractory+Prostate+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T20:35:11.163Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06826768",
      "title": "A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "REGN5678",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2025-07-09",
      "completion_date": "2029-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06826768"
    },
    {
      "nct_id": "NCT00428220",
      "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Metastatic Renal Cell Cancer",
        "Non-Small Cell Lung Cancer",
        "Thyroid Cancer",
        "Advanced/Metastatic Non-Small Cell Lung Cancer",
        "Advanced Gastric Cancer",
        "Gastrointestinal Stromal Tumor",
        "Hepatocellular Carcinoma",
        "Pancreatic Islet Cell Carcinoma",
        "Pancreatic Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "sunitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 223,
      "start_date": "2007-07",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2019-06-27",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 15,
      "location_summary": "Atlanta, Georgia • Maywood, Illinois • Iowa City, Iowa + 7 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Maywood",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428220"
    },
    {
      "nct_id": "NCT01385293",
      "title": "BKM120 in Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Metastatic (Spread to Other Areas of the Body)"
      ],
      "interventions": [
        {
          "name": "BKM120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew J. Armstrong, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2011-08",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-05-19",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 3,
      "location_summary": "Durham, North Carolina • Portland, Oregon • Seattle, Washington",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01385293"
    },
    {
      "nct_id": "NCT01335204",
      "title": "Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Cabazitaxel plus bavituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2011-06",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2018-07-13",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01335204"
    },
    {
      "nct_id": "NCT04726332",
      "title": "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Malignant",
        "Epithelial Ovarian Cancer",
        "Triple Negative Breast Cancer",
        "Hormone Receptor Positive Breast Carcinoma",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "XL102",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2021-02-10",
      "completion_date": "2024-05-02",
      "has_results": false,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04726332"
    },
    {
      "nct_id": "NCT00081601",
      "title": "Study of CEP-701 in Treatment of Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "CEP-701",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cephalon",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2004-03",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2012-08-24",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081601"
    },
    {
      "nct_id": "NCT04477512",
      "title": "Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Hormone Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Peripheral blood collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 18,
      "start_date": "2021-02-19",
      "completion_date": "2025-09-10",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04477512"
    },
    {
      "nct_id": "NCT07050433",
      "title": "COMPASS Study for Metastatic Castration-resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "CXCR2 as a biomarker",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 48,
      "start_date": "2025-08-07",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Ann Arbor, Michigan • Durham, North Carolina",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07050433"
    },
    {
      "nct_id": "NCT06636123",
      "title": "GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Investigational Agent Administration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2025-02-18",
      "completion_date": "2031-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06636123"
    },
    {
      "nct_id": "NCT02025413",
      "title": "Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Progressive Castration-resistant Prostate Cancer",
        "Metastatic Progressive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2011-11",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2018-12-20",
      "last_synced_at": "2026-06-26T20:35:11.163Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02025413"
    }
  ]
}